載入中
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
最新資料
US$196.48
+US$9.02 · +4.81%
盤中時間採用ET。市場資料可能有所延遲。
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
盤中時間採用ET。市場資料可能有所延遲。
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 19.44億 USD | 31.99億 USD | 68.48億 USD | 188.75億 USD | 177.36億 USD |
| 銷貨成本 | 8.68億 USD | 14.64億 USD | 46.93億 USD | 54.16億 USD | 26.17億 USD |
| 毛利 | 10.76億 USD | 17.35億 USD | 21.55億 USD | 134.59億 USD | 151.19億 USD |
| 研究與開發 | 31.32億 USD | 45.43億 USD | 48.45億 USD | 32.95億 USD | 19.91億 USD |
| 銷售、一般及管理費用 | 10.18億 USD | 11.74億 USD | 15.49億 USD | 11.32億 USD | 5.67億 USD |
| 營業費用 | 41.5億 USD | 56.8億 USD | 63.94億 USD | 40.39億 USD | 18.23億 USD |
| 利息收入 | 3.14億 USD | 4.25億 USD | 4.21億 USD | 2億 USD | 1800萬 USD |
| 利息支出 | 1000萬 USD | 2400萬 USD | 3800萬 USD | 2900萬 USD | 1800萬 USD |
| 折舊和攤銷 | 2.15億 USD | 1.89億 USD | 6.21億 USD | 3.48億 USD | 2.32億 USD |
| 營業利益 | −30.74億 USD | −39.45億 USD | −42.39億 USD | 94.2億 USD | 132.96億 USD |
| 淨利 | −28.22億 USD | −35.61億 USD | −47.14億 USD | 83.62億 USD | 122.02億 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T1338.38億0.10%129.41兆 JPY0.09%¥122,900-0.41%
Vanguard Morningstar Total Stock Market ETFVTI15.93億0.07%2.3兆 USD0.03%US$381.03-0.40%
Vanguard S&P 500 ETFVOO13.17億0.07%1.8兆 USD0.03%US$714.34-0.26%
Vanguard Morningstar Small-Cap ETFVB11.53億0.62%1853億 USD0.03%US$286.98-1.41%
iShares Core S&P 500 ETFIVV9.27億0.10%8996.25億 USD0.03%US$780.58-0.25%
State Street SPDR S&P 500 ETFSPY8.45億0.10%8190.39億 USD0.09%US$777.22-0.24%
Vanguard Morningstar Small-Cap Value ETFVBR7.32億1.07%682億 USD0.05%US$232.17-1.32%
iShares Biotechnology ETFIBB5.18億4.98%104.01億 USD0.44%US$203.34+0.12%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
